Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to $5.9 million.

  • NovaBay Pharmaceuticals' Shares Outstanding (Weighted Average) rose 40874.46% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 40874.46%. This contributed to the annual value of $3.4 million for FY2024, which is 273000.0% up from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $5.9 million for Q3 2025, which was up 40874.46% from $5.8 million recorded in Q2 2025.
  • NovaBay Pharmaceuticals' Shares Outstanding (Weighted Average)'s 5-year high stood at $44.9 million during Q3 2021, with a 5-year trough of $91000.0 in Q2 2023.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $1.6 million (2022), whereas its average is $8.5 million.
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Shares Outstanding (Weighted Average) crashed by 9657.51% in 2022, and later soared by 432333.33% in 2025.
  • Over the past 5 years, NovaBay Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $1.2 million in 2021, then increased by 29.11% to $1.6 million in 2022, then tumbled by 92.55% to $120000.0 in 2023, then soared by 2730.0% to $3.4 million in 2024, then surged by 73.03% to $5.9 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $5.9 million in Q3 2025, compared to $5.8 million in Q2 2025 and $5.3 million in Q1 2025.